Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Chong‐Jen Yu's publication output changed over time?
ScholarIQpublication output · 1992–2023
Output grew0% over the shown period — from 1 works in 1992 to 1 in 2023.
1
1
1
1
1
3
1
2
1
199220072008201120122015201720202023
What are the most-cited papers on Chong‐Jen Yu?
ScholarIQmost cited works
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
New England Journal of Medicine. 20201,780 CitationsOPEN ACCESS
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean, Cameron Brennan, Jin‐Yuan Shih, Gregory J. Riely, Agnès Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, János Szőke, Stephen Broderick, Marissa N. Balak, W.C. Chang, Chong‐Jen Yu, Adi F. Gazdar, Harvey I. Pass, Valerie W. Rusch, William L. Gerald, Shiu‐Feng Huang, Pan‐Chyr Yang, Vincent A. Miller, Marc Ladanyi, Chih-Hsin Yang, William Pao
Proceedings of the National Academy of Sciences. 20071,589 Citations
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, Yi‐Long Wu, Luis Paz‐Ares, Juergen Wolf, Sarayut Lucien Geater, С. В. Орлов, Diego Cortinovis, Chong‐Jen Yu, Maximillian Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro
The Lancet. 20171,157 Citations
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Mok, Martin Schüler, Nobuyuki Yamamoto, Chong‐Jen Yu, Sai‐Hong Ignatius Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi‐Long Wu
The Lancet Oncology. 2015988 Citations
Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia
Guangchang Pei, Zhiguo Zhang, Jing Peng, Liu Liu, Chunxiu Zhang, Chong‐Jen Yu, Zufu Ma, Yi Huang, Wei Liu, Ying Yao, Rui Zeng, Gang Xu
Journal of the American Society of Nephrology. 2020818 CitationsOPEN ACCESS
Related on ScholarIQ
National Taiwan University Hospital
Institution
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Paper
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib
Paper
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Paper
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
Paper
Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia
Paper